This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Shionogi strongly supports the
With the rapid development of novel gene therapies also comes the need for new payment models that can accommodate the high cost of accessing these treatments. ... A report from The Alliance for Regenerative Medicine (ARM) published in July last year
b) Reimbursement models are evolving. Until recently, reimbursement was rather indirect, for example, by using digital medicines for safeguarding pay-for-performance deals and value-based reimbursement models. ... The next step is direct reimbursement of
Our NHS is in a unique position to take a global lead in testing new payment models. ... The pilot scheme also reflects a new willingness and capability in the UK to try out new reimbursement models, primarily led by NHS England.
Existing models include conditional reimbursement, such as England’s Cancer Drugs Fund and Scotland’s fund for ultra-orphan drugs. ... The report recommends a number of key measures, including:. A quick adoption of new payment models such as
The Advanced Therapies &Regenerative Medicine congress, hosted by Terrapinn on Thursday, brought together a panel of experts who discussed emerging reimbursement and financing models in the US and Europe. ... However the changing dynamics of the pipeline
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Any of these issues can increase cost or risk. Adapting pricing and reimbursement models to accommodate these therapies could be a significant challenge, especially for higher-cost drugs or those involving ... Manufacturers will need to restructure
Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions such as
This pathway would better align the current regulatory, reimbursement, evaluation and diffusion processes, and provide companies with tailored support in navigating the new, simplified system. ... reimbursement models” for greater patient access.
In 2015 there were 8, 104 products on the reimbursement list, with 292 new ones added. ... company. Alternative reimbursement models. The SGK was first authorised in September 2014 to develop 'alternative reimbursement models' as a new channel through
These emerging regulatory and reimbursement models all aim to make treatment provision and access more sensitive to the evolving evidence base, and all require RWD. ... models. Where the appropriate safeguards are in place, authorisation should be based
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
As a business, Orchard Therapeutics want to introduce as many therapies as possible and, in order to enable a broader reach, are eager to work with regulators to explore reimbursement models
The cycle of behavioural change. It’s already certain that more pragmatic reimbursement models will be required to deal with the cost of these new treatments as upfront payment will be
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...